ArticleCirculation research2010
Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium.
Article in Circulation research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 1 synthesis or guideline pooled it, 238 citations in OpenAlex.
- Pooled it
- Trial
- Regenerative effects of myogenic gene transfected MSC derived exosomes on radiation esophagitis.Tissue engineering and regenerative medicine · 2026Article
- Premature ovarian insufficiency restoration after chemotherapy: current achievements and future prospects on its treatment or management.Journal of ovarian research · 2025Review
- CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis.iScience · 2025Article
- Cytokine modulation in pelvic organ prolapse and urinary incontinence: from molecular insights to therapeutic targets.Molecular medicine (Cambridge, Mass.) · 2024Review
- Engineered Mesenchymal Stem Cells as Treatment for Cancers: Opportunities, Clinical Applications and Challenges.The Malaysian journal of medical sciences : MJMS · 2024Review
- Genetically modified mesenchymal stromal cells: a cell-based therapy offering more efficient repair after myocardial infarction.Stem cell research & therapy · 2024Review
- Synergistic Enhancement of Photodynamic Cancer Therapy with Mesenchymal Stem Cells and Theranostic Nanoparticles.ACS applied materials & interfaces · 2024Article
- The Role of Mesenchymal Stem Cells in Modulating Adaptive Immune Responses in Multiple Sclerosis.Cells · 2024Review
- Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges.Signal transduction and targeted therapy · 2024Review
- Unlocking the Potential of Extracellular Vesicles as the Next Generation Therapy: Challenges and Opportunities.Tissue engineering and regenerative medicine · 2024Review
- Review
- Mesenchymal stem cell-based therapy for female stress urinary incontinence.Frontiers in cell and developmental biology · 2023Review
- Targeted cell delivery of mesenchymal stem cell therapy for cardiovascular disease applications: a review of preclinical advancements.Frontiers in cardiovascular medicine · 2023Review
- CSF2RB overexpression promotes the protective effects of mesenchymal stromal cells against ischemic heart injury.Theranostics · 2023Article
- Mesenchymal stem cells to treat female infertility; future perspective and challenges: A review.International journal of reproductive biomedicine · 2022Review
- An Improved Monkey Model of Myocardial Ischemic Infarction for Cardiovascular Drug Development.Cardiovascular toxicology · 2022Article
- Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway.Stem cell research & therapy · 2022Article
- Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease.International journal of molecular sciences · 2022Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
rationaleAlthough mesenchymal stem cell (MSC) transplantation has been shown to promote cardiac repair in acute myocardial injury in vivo, its overall restorative capacity appears to be restricted mainly because of poor cell viability and low engraftment in the ischemic myocardium. Specific chemokines are upregulated in the infarcted myocardium. However the expression levels of the corresponding chemokine receptors (eg, CCR1, CXCR2) in MSCs are very low. We hypothesized that this discordance may account for the poor MSC engraftment and survival.
objectiveTo determine whether overexpression of CCR1 or CXCR2 chemokine receptors in MSCs augments their cell survival, migration and engraftment after injection in the infarcted myocardium. METHODS AND
resultsOverexpression of CCR1, but not CXCR2, dramatically increased chemokine-induced murine MSC migration and protected MSC from apoptosis in vitro. Moreover, when MSCs were injected intramyocardially one hour after coronary artery ligation, CCR1-MSCs accumulated in the infarcted myocardium at significantly higher levels than control-MSCs or CXCR2-MSCs 3 days postmyocardial infarction (MI). CCR1-MSC-injected hearts exhibited a significant reduction in infarct size, reduced cardiomyocytes apoptosis and increased capillary density in injured myocardium 3 days after MI. Furthermore, intramyocardial injection of CCR1-MSCs prevented cardiac remodeling and restored cardiac function 4 weeks after MI.
conclusionsOur results demonstrate the in vitro and in vivo salutary effects of genetic modification of stem cells. Specifically, overexpression of chemokine receptor enhances the migration, survival and engraftment of MSCs, and may provide a new therapeutic strategy for the injured myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.